Abstract: Disclosed herein are methods for determining the fertility of a sperm sample or a source of a sperm sample; the methods comprising labeling the sperm sample with a zinc probe, identifying presence and/or localization of zinc associated with spermatozoa in the sample and determining the fertility of the sample based on the zinc presence and/or localization in the spermatozoa as compared to a reference pattern associated with non-capacitated spermatozoa or a reference pattern associated with sperm capacitation. Also disclosed are methods of improving sperm fertility and/or decreasing premature capacitation while handling, storing, or transporting semen, the methods comprising adding exogenous zinc to a sperm sample or semen sample. Also disclosed are compositions for improving sperm fertility and/or reducing premature capacitation, the compositions comprising exogenous zinc ions.

Abstract: The present invention concerns the use of compositions and methods of regulating or evaluating fertility in an animal, in particular a mammal. In various embodiments of the invention, methods of contraception include inhibiting proteasome activity of a gamete, in particular spermatozoon. Proteasomal activity may be inhibited in vitro or in vivo. Inhibitors of the proteasome pathway include, but are not limited to small molecules, peptides, polypeptides (e.g., antibodies and the like) and affinity reagents that bind various components of the proteasome pathway (e.g., aptamers, etc.). In some embodiments, the activity of the proteasome pathway or the activity of a component in the proteasome pathway is inhibited by antibodies that bind and inhibit one or more components of the proteasome pathway.

Abstract: The present invention concerns the use of compositions and methods of regulating or evaluating fertility in an animal, in particular a mammal. In various embodiments of the invention, methods of contraception include inhibiting proteasome activity of a gamete, in particular spermatozoon. Proteasomal activity may be inhibited in vitro or in vivo. Inhibitors of the proteasome pathway include, but are not limited to small molecules, peptides, polypeptides (e.g., antibodies and the like) and affinity reagents that bind various components of the proteasome pathway (e.g., aptamers, etc.). In some embodiments, the activity of the proteasome pathway or the activity of a component in the proteasome pathway is inhibited by antibodies that bind and inhibit one or more components of the proteasome pathway.